Huw D. Vater

Reagent-Controlled Asymmetric Homologation of Boronic Esters by Enantioenriched Main-Group Chiral Carbenoids

Paul R. Blakemore, Stephen P. Marsden, Huw D. Vater · Organic Letters · 2006 · 105 citations

Evaluation of 5-(Trifluoromethyl)-1,2,4-oxadiazole-Based Class IIa HDAC Inhibitors for Huntington’s Disease

Andrew J. Stott, Michel Maillard, Vahri Beaumont et al. · ACS Medicinal Chemistry Letters · 2021 · 40 citations · Full text

Developing HDAC4-Selective Protein Degraders To Investigate the Role of HDAC4 in Huntington’s Disease Pathology

Natsuko Macabuag, William Esmieu, Perla Breccia et al. · Journal of Medicinal Chemistry · 2022 · 29 citations · Full text

Optimization of Potent and Selective Ataxia Telangiectasia-Mutated Inhibitors Suitable for a Proof-of-Concept Study in Huntington’s Disease Models

Leticia Toledo‐Sherman, Perla Breccia, Roger Cachope et al. · Journal of Medicinal Chemistry · 2019 · 24 citations · Full text

Genetics, Molecular Biology, Pharmacotherapy +17

The importance of plasma protein and tissue binding in a drug discovery program to successfully deliver a preclinical candidate

Elizabeth Hann, Karine Malagu, Andrew J. Stott et al. · Progress in medicinal chemistry · 2022 · 20 citations

Tissue Binding, Drug Discovery Program, Drug Target +9